Stock Track | Hims & Hers Health Plunges 12.39% After Q2 Revenue Miss Despite Earnings Beat

Stock Track
08/05

Shares of Hims & Hers Health Inc. (HIMS) tumbled 12.39% in a 24-hour period following the release of its second quarter 2025 financial results. The telehealth company's stock decline came despite beating earnings estimates, as revenue fell short of expectations.

Hims & Hers reported Q2 revenue of $544.8 million, marking a substantial 73% increase year-over-year. However, this figure missed the analyst estimates of $551.6 million. On a positive note, the company's earnings per share (EPS) of $0.17 surpassed the expected $0.15. The number of subscribers grew by 31% to over 2.4 million compared to the previous year.

The revenue miss was primarily attributed to a decline in the company's GLP-1 weight-loss drug business, which generated $190 million in online revenue during the second quarter, down from $230 million in the first quarter. Additionally, the company's sexual health business experienced a slowdown. Despite these challenges, Hims & Hers maintained its full-year 2025 guidance, projecting revenue between $2.3 billion and $2.4 billion. The company emphasized its commitment to providing personalized, high-quality care and entering new, high-impact specialties, but investors seemed concerned about the short-term revenue challenges and potential regulatory hurdles in the weight-loss drug market.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10